Table 1 Patient Characteristics

Clinical characteristic	Cilta-cel N (%)		Ide-cel N (%)		P value
Total (N = 39)	23	(59.0)	16	(41.0)
Gender					0.440
Male	13	(54.2)	10	(66.7)
Female	11	(45.8)	5	(33.3)
Age					0.217
≥ 70 years	7	(33.3)	8	(50.0)
<70 years	16	(66.7)	8	(50.0)
Race					0.448
Black	6	(26.1)	6	(37.5)
White	17	(73.9)	10	(62.5)
Disease characteristics
IgG / IgA / IgD / IgM / LC	15 / 5 / 1 / 1 / 1		9 / 4 / 0 / 0 / 3		0.616
Oligo-/Non-secretory	4	(17.4)	1	(6.3)	0.306
Extramedullary Disease	5	(22.7)	3	(18.8)	0.767
Creatinine Clearance <60 mL/min	6	(26.1)	4	(25.0)	0.939
R-ISS 2/3	11	(47.8)	6	(37.5)	0.522
Del17p	6	(27.3)	3	(25.0)	0.886
t(4;14)	2	(9.5)	1	(7.7)	0.855
Prior lines of treatments (median/range)	5.0	(5.0)	5.5	(8.0)	0.640
Prior therapies
ASCT	15	(65.2)	11	(68.8)	0.818
Lenalidomide	22	(95.7)	16	(100.0)	0.398
Pomalidomide	21	(91.3)	16	(100.0)	0.226
Bortezomib	21	(91.3)	15	(93.8)	0.778
Carfilzomib	20	(87.0)	14	(87.5)	0.960
Anti-CD38 mAb	23	(100.0)	16	(100.0)	0.999
Bridging therapy	18	(78.3)	7	(43.8)	*0.043*
Cytokine Release Syndrome
Grade 1−2	20	(87.0)	14	(87.5)	0.960
Tocilizumab use	19	(82.6)	13	(81.3)	0.913
ICANS
Grade 1-2	5	(22.7)	2	(14.3)	0.533
Grade 3	3	(13.6)	2	(14.3)	0.956
Steroid use	16	(69.6)	8	(50.0)	0.217
Other types of neurotoxicities	6	(26.1)	0	(0.0)	*0.064*
Other complications
Infection	18	(78.3)	2	(12.5)	*<0.0001*
ICU Care	5	(21.7)	2	(12.5)	0.460
Outcome
Overall response rate	21	(91.3)	13	(81.3)	0.356
Complete response rate	14	(63.6)	9	(56.3)	0.646
Progression-free survival (PFS)	18.0 months		16.6 months		0.219

TTo compare individual clinical characteristics between groups a Chi Square test was used. A Kolmogorov-Smirnov test was used to compare progression-free survival between groups. A p = 0.05 was considered statistically significant. No adjustments were made for multiple comparisons. Italic numbers indicate p-values for individual statistical tests and bold numbers indicate differences that were statistically significant or trended towards statistical significance.

Search